Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) shares dropped 2% during trading on Tuesday . The stock traded as low as $6.79 and last traded at $6.83, with a volume of 848,635 shares traded. The stock had previously closed at $6.97.

PGNX has been the topic of several recent analyst reports. Brean Capital set a $14.00 price target on Progenics Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 5th. Zacks Investment Research upgraded Progenics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a research note on Tuesday, July 26th. BTIG Research reiterated a “buy” rating and issued a $9.00 price target on shares of Progenics Pharmaceuticals in a research note on Wednesday, July 20th. Jefferies Group reiterated a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Friday, June 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Progenics Pharmaceuticals in a research note on Friday, July 22nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Progenics Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $9.95.

The stock’s 50 day moving average is $5.97 and its 200 day moving average is $5.01. The stock’s market cap is $478.70 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.05. The company earned $8.50 million during the quarter, compared to analyst estimates of $6.33 million. The company’s revenue was up 337.6% compared to the same quarter last year. During the same period last year, the company posted ($0.17) earnings per share. On average, equities analysts expect that Progenics Pharmaceuticals Inc. will post $0.13 EPS for the current fiscal year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.